of 7 days of treatment with two doses of dotinurad monotherapy, and to evaluate the effect of dotinurad, as monotherapy and in combination with allopurinol, versus allopurinol monotherapy ...

Choi notes that many of these lifestyle changes will not only reduce uric acid levels and the risk of recurrent gout but will also improve the health status of those with comorbidities ...

Methods: In this prospective study, patients with gout receiving urate lowering therapy with benzbromarone were assigned to two groups, a renal underexcretion and an unclassified type. The primary ...

Japanese drugmaker Eisai (TYO: 4523) today announced that it has received approval for Urece (dotinurad) from the National Medical Products Administration (NMPA) in China as a treatment for gout ...

MACHINE LEARNING MODEL USING DATA THAT CAN BE COLLECTED IN DAILY MEDICAL EXAMINATIONS BY PRIMARY CARE PHYSICIANS TOKYO, Feb 14, 2025 - (JCN Newswire) - Oita University and Eisai Co., Ltd. (Eisai) ...

OBJECTIVES To study the efficacy of allopurinol and benzbromarone to reduce serum urate concentrations in patients with primary chronic gout. METHODS Prospective, parallel, open study of 86 ...

Objective: The study focuses on comparing the efficacy of a low-dose combination of febuxostat and benzbromarone versus each drug used alone for the treatment of gout. Methods: A prospective, ...

After hours: February 18 at 4:34:00 PM EST Loading Chart for FBIOP ...

Results: Combination therapy of fenofibrate or losartan with anti-hyperuricaemic agents, which included benzbromarone (50 mg once daily) or allopurinol (200 mg twice a day), significantly reduced ...